PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 10, 2014, Pages 3694-3699

  Cusano, Natalie E ^a   Rubin, Mishaela R ^a   McMahon, Donald J ^a   Irani, Dinaz ^a   Anderson, Laura ^a   Levy, Elizabeth ^a   Bilezikian, John P ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; CREATININE; PARATHYROID HORMONE; PHOSPHATE; RECOMBINANT PARATHYROID HORMONE; VITAMIN D; RECOMBINANT PROTEIN;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPOPARATHYROIDISM; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; QUALITY OF LIFE; SHORT FORM 36; ADOLESCENT; CLINICAL TRIAL; EMOTION; HEALTH SURVEY; LONGITUDINAL STUDY; MIDDLE AGED; PSYCHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; EMOTIONS; FEMALE; HEALTH SURVEYS; HUMANS; HYPOPARATHYROIDISM; LONGITUDINAL STUDIES; MALE; MENTAL HEALTH; MIDDLE AGED; PARATHYROID HORMONE; QUALITY OF LIFE; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907638333     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2267     Document Type: Article

References (28)

1. Bilezikian JP, Khan A, Potts JT, Jr, et al. Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J Bone Miner Res. 2011;26:2317-2337.
2. Shoback D. Clinical practice. Hypoparathyroidism. New Engl J Med. 2008;359:391-403.
3. Cusano NE, Rubin MR, Sliney J, Jr, Bilezikian JP. Mini-review: new therapeutic options in hypoparathyroidism. Endocrine. 2012;41:410-414.
4. Mitchell DM, Regan S, Cooley MR, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:4507-4514.
5. Winer KK, Ko CW, Reynolds JC, et al. Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium. J Clin Endocrinol Metab. 2003;88:4214-4220.
6. Winer KK, Sinaii N, Reynolds J, Peterson D, Dowdy K, Cutler GB Jr. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium. J Clin Endocrinol Metab. 2010;95:2680-2688.
7. Rubin MR, Sliney J, Jr., McMahon DJ, Silverberg SJ, Bilezikian JP. Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos Int. 2010;21:1927-1934.
8. Rubin MR, Dempster DW, Sliney J Jr., et al. PTH (1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J Bone Miner Res. 2011;26:2727-2736.
9. Winer KK, Zhang B, Shrader JA, et al. Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism. J Clin Endocrinol Metab. 2012;97:391-399.
10. Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH (1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26:2358-2370.
11. Cusano NE, Rubin MR, McMahon DJ, et al. Therapy of hypoparathyroidism with PTH (1-84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98:137-144.
12. Mannstadt M, Clarke BL, Vokes T, et al. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1:275-283.
13. Arlt W, Fremerey C, Callies F, et al. Well-being, mood and calcium homeostasis in patients with hypoparathyroidism receiving standard treatment with calcium and vitamin D. Eur J Endocrinol. 2002;146:215-222.
14. Cusano NE, Rubin MR, McMahon DJ, et al. The effect of PTH (1-84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98:2356-2361.
15. Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH (1-84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25:1717-1726.
16. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
17. RAND Health 2010 Medical Outcomes Study: 36-Item Short Form Survey Scoring Instructions. Available at: http://wwwrandorg/health/surveys-tools/mos/mos-core-36item-scoringhtml.
18. te Vaarwerk MJ, Gaal EA. Psychological distress and quality of life in drug-using and non-drug-using HIV-infected women. Eur J Public Health. 2001;11:109-115.
19. O'Brien PE, Dixon JB, Brown W, et al. The laparoscopic adjustable gastric band (Lap-Band): a prospective study of medium-term effects on weight, health and quality of life. Obes Surg. 2002;12:652-660.
20. van Baalen B, Odding E, van Woensel MP, Roebroeck ME. Reliability and sensitivity to change of measurement instruments used in a traumatic brain injury population. Clin Rehabil. 2006;20:686-700.
21. Seguin R, Lamonte M, Tinker L, et al. Sedentary behavior and physical function decline in older women: findings from the women's health initiative. J Aging Res. 2012;2012:271589.
22. Usdin TB, Gruber C, Bonner TI. Identification and functional expression of a receptor selectively recognizing parathyroid hormone, the PTH2 receptor. J Biol Chem. 1995;270:15455-15458.
23. Bagó AG, Dimitrov E, Saunders R, et al. Parathyroid hormone 2 receptor and its endogenous ligand tubero in fundibular peptide of 39 residues are concentrated in endocrine, viscerosensory and auditory brain regions in macaque and human. Neuroscience. 2009;162:128-147.
24. Balabanov S, Tollner U, Richter HP, Pohlandt F, Gaedicke G, Teller WM. Immunoreactive parathyroid hormone, calcium, and magnesium in human cerebrospinal fluid. Acta Endocrinol (Copenh). 1984;106:227-233.
25. Joborn C, Hetta J, Niklasson F, et al. Cerebrospinal fluid calcium, parathyroid hormone, and monoamine and purine metabolites and the blood-brain barrier function in primary hyperparathyroidism. Psychoneuroendocrinology. 1991;16:311-322.
26. Care AD, Bell NH. Evidence that parathyroid hormone crosses the blood-brain barrier. Proceedings of the IXth International Conference on Calcium Regulating Hormones and Bone Metabolism; Nice, France; 1986.
27. Fox J, Wells D, Garceau R. Relationships between pharmacokinetic profile of human PTH (1-84) and serum calcium response in postmenopausal women following 4 different methods of administration. J Bone Miner Res. 2011;26. Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=cb1c7954-4672-41f1-8b55-9a70ec107b6f. Accessed April 23, 2014.
28. Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH (1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28:2232-2243.